Comparative Pharmacology
Head-to-head clinical analysis: GEODON versus INVEGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEODON versus INVEGA.
GEODON vs INVEGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ziprasidone is an atypical antipsychotic with high affinity for dopamine D2 and serotonin 5-HT2A receptors; it also antagonizes 5-HT2C, 5-HT1D, alpha1-adrenergic, and histamine H1 receptors, and moderately inhibits serotonin and norepinephrine reuptake.
Paliperidone is the major active metabolite of risperidone. It is a benzisoxazole derivative antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors. It also acts as an antagonist at α1 and α2 adrenergic receptors and H1 histaminergic receptors. It has no affinity for muscarinic receptors.
20 mg orally twice daily with food; may titrate to 40-80 mg orally twice daily; maximum 80 mg orally twice daily. For acute treatment, IM 10-20 mg as needed up to 40 mg/day.
Oral: 6 mg once daily; may increase to 9 mg/day if needed. IM (extended-release): 234 mg on day 1, 156 mg on day 8, then 117 mg monthly; adjust within range 39-234 mg per month.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for oral ziprasidone; after intramuscular administration, half-life is about 2-5 hours. This short half-life may require twice-daily dosing for oral therapy.
Terminal elimination half-life is approximately 23-29 hours for oral administration (paliperidone extended-release). Once-daily dosing achieves steady-state within 4-5 days.
Primarily hepatic metabolism via aldehyde oxidase and CYP3A4. Approximately 20% excreted renally as unchanged drug, with the remainder as metabolites (mostly fecal).
Primarily renal: 59-80% of dose excreted unchanged in urine (as parent drug and metabolites). Fecal: ~20-30%. Biliary elimination is minimal.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic